Integrity-based, the market is changing, and integrity will never change...
Language: 简体中文简体中文 line EnglishEnglish

Company news

The third round of procurement is about to attack, how to deal with pharmaceutical enterprises?

Recently, the state organized the joint procurement office of centralized drug procurement and use to hold a forum on centralized online drug procurement to solicit the opinions of some enterprises on the third batch of national bulk procurement. In this regard, the industry believes that the third batch of centralized drug procurement will be put on the agenda, or will meet with you in July. So how should pharmaceutical enterprises deal with the trend of drug purchase with quantity in exchange for price?  
Seize the opportunity of bidding
Looking at the current procurement with volume, although the price reduction wave after wave, but for a large number of ordinary generic drugs, the varieties involved are less, the impact is still relatively controllable, and the market opportunities still exist. After all, 30-50 catalogues will become the norm, but it will take a long time to cover most of the drugs. Therefore, in this period of time, such as record purchase, sunshine online, self paid drug price negotiation purchase, even point-to-point negotiation procurement of monomer hospitals, professional chain pharmacies and DTP pharmacies will become important opportunities for the development of pharmaceutical enterprises. Pharmaceutical enterprises can further dilute various expenses and increase sales by winning more bids.
Recognize the situation of medical reform and accelerate the transformation
In fact, medical policy is a part of the overall layout of health care reform. From the perspective of macro factors such as population aging and external economic situation, the sustainable development of medical insurance fund is a top-level policy design with higher priority than the development of pharmaceutical industry. Pharmaceutical enterprises that the state is happy to see comply with the policy direction through industrial upgrading. Therefore, under the background that the state controls medical insurance fees through the normalization of procurement with quantity, most pharmaceutical enterprises can do is to seize the time to carry out industrial upgrading and transformation, and do not want miracles or take advantage of policy loopholes. Similarly, circulation enterprises and retail pharmacies also need to consider the market pattern after volume purchase to make up for the loss of prescription return to hospital and unit price caused by its impact. Marketing personnel in pharmaceutical enterprises should recognize the situation, strive to improve their professional ability and expand their multi position work experience, so as to avoid being eliminated by the times.
Developing towards the integration of raw materials and preparations
At present, with the continuous deepening of volume procurement, many generic pharmaceutical products are facing the test of "price" and "quantity". Due to the high demand for production capacity and the rise of API, for pharmaceutical enterprises, the industrial pressure will be distributed to all stages from API procurement to drug production and distribution. In this context, the industry believes that enterprises with the development mode of API preparation integration will gradually highlight their advantages. Therefore, some generic pharmaceutical enterprises that do not have the ability of direct transformation and innovation can gradually reduce the production cost by "raw material preparation integration", and also can reduce the impact of price fluctuation of API on enterprises. It is understood that many enterprises have listed the integrated development of API and preparation into the company's long-term development strategy, and even many enterprises have begun to build new plant areas to cooperate with the development.
epilogue
Generally speaking, the normal operation of drug and medical device procurement with quantity has become the general trend. With the promotion of mass purchase mode and nationwide expansion, generic drugs without technical barriers will gradually return to the profit level of manufacturing industry, and the era of high gross profit of generic drugs has ended. In the future, only pharmaceutical enterprises with R & D and innovation capabilities and rich product lines and strong pressure resistance can have more opportunities and develop better in the increasingly competitive market.